TY - JOUR
AU1 - Kruse‐Jarres, R.
AU2 - Gilsenan, A.
AU3 - Spears, J.
AU4 - Kaye, J. A.
AB -  Haemophilia A (factor VIII [FVIII] deficiency) is a rare bleeding disorder and the most common type of haemophilia. Although largely inherited, approximately 30% of haemophilia A cases are due to spontaneous gene mutations in patients with no family history of haemophilia. Several recombinant and plasma‐derived factor VIII (pdFVIII) products are available to prevent or treat bleeding caused by haemophilia and reduce the risk of long‐term complications. The most serious treatment complication for patients with haemophilia A is the development of inhibitory IgG antibodies to FVIII . Inhibitors result in rapid clearance of infused FVIII and marked reduction or absence of efficacy. Recombinant activated factor VII (rFVIIa) and FVIII inhibitor bypassing activity are two agents used to treat acute bleeding in patients with inhibitors . However, inhibitor eradication is the goal of long‐term management. Immune tolerance induction (ITI) therapy using frequent administration of high FVIII doses, sometimes in combination with immunomodulatory or immunosuppressive drugs, is the only strategy that has been shown to achieve antigen‐specific tolerance . Other than the International Immune Tolerance Study , few prospective studies have been conducted that describe how patients with haemophilia A respond to ITI therapy. Published studies of the efficacy and safety 
TI - Prospective, observational study of plasma‐derived factor VIII /von Willebrand factor in immune tolerance induction: the PRISM registry
JF - Haemophilia
DO - 10.1111/hae.12590
DA - 2015-03-01
UR - https://www.deepdyve.com/lp/wiley/prospective-observational-study-of-plasma-derived-factor-viii-von-d0z0PCi9rJ
SP - e122
EP - e124
VL - 21
IS - 2
DP - DeepDyve
ER -